Eliquis (Apixaban) is an oral antiplatelet belonging to the class of direct factor Xa inhibitors. It is manufactured by Bristol-Myers Squibb and Pfizer under the trade name Eliquis. It acts by inhibiting Factor Xa, which is a key blood clotting protein that decreases the level of a thrombin, thus Eliquis indirectly decreases clot formation. Eliquis was approved by the U.S Food and Drug Administration FDA on December 28, 2012, for the prevention of stroke in people with Atrial fibrillation.
Eliquis is used for
- Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation
- Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Treatment of Deep Vein Thrombosis
- Treatment of Pulmonary Embolism
- Reduction in the Risk of Recurrence of DVT and PE
In June 2014, a patient started on Eliquis died of gastrointestinal bleeding as a complication within two months. It was observed that Eliquis can increase the risk of uncontrollable bleeding, and is more prone when taken at the same time with Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).
There has been no recall of Eliquis as of November 2017.
Eliquis does not have an antidote to stop the bleeding complications.